Wegovy approved in Canada to combat risk of non fatal-heart attack – National

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Wegovy approved in Canada to combat risk of non fatal-heart ******* – National

Descrease article font size

Increase article font size

Canada’s health regulator has approved Novo Nordisk’s weight loss ***** Wegovy to reduce the risk of nonfatal heart ******* or myocardial infarction in some adults, the Danish drugmaker said on Wednesday.

Wegovy has become the first approved treatment in Canada to address both obesity and the risk of heart-related conditions in adults with established cardiovascular ********, according to Novo Nordisk.

The ********* Union health regulator recently backed the ***** for reducing the risk of major cardiovascular events and strokes in overweight or obese adults without diabetes.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.

Wegovy is also approved in the U.K. and the U.S. to lower the risk of serious heart problems or strokes in overweight and obese adults.

The *****, chemically known as semaglutide, has been authorized in Canada to treat obesity since 2021.

This is the hidden content, please

• Sign In
• or
• Sign Up

/applications/core/interface/js/spacer.png">

4:17
Ozempic maker bringing weight-loss ***** Wegovy to Canada

This is the hidden content, please

• Sign In
• or
• Sign Up

#Wegovy #approved #Canada #combat #risk #fatalheart #******* #National

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up